Front Range Biosciences
617-320-8743
http://www.frontrangebio.com/
Key contact
Name | Title |
---|---|
Dr. Jon Vaught | CEO |
"FRB is not just keeping up with the industry, it's defining it," says Vikas Desai, Founder and Partner at Welcan Capital. "The ability to execute on their exponential growth plan, while developing innovative products to meet thriving market demand, proves FRB is an industry pace-setter and in position to remain the leader amongst the competition."
"The continued global advancement of cannabis legalization is creating an opportunity for unprecedented growth and innovation in agriculture," says Jon Vaught, CEO and Co-Founder of Front Range Biosciences. "The introduction of cannabis to the agricultural market as a new crop with medical, nutritional and industrial applications presents a unique opportunity for us to use modern biotechnology to provide sustainable solutions for farmers around the world."
With the explosive growth of both the hemp and cannabis industries, the biotech race to provide high-quality genetics is in full swing. Supply for reliable, clean cannabis plants leveraging tissue culture technology is still less than 1% of total demand. FRB is driving the advancement of hemp and cannabis agriculture with its innovative varietal development platform and Clean Stock program that provides growers with best in class solutions for this exciting new crop. The Insider Round enables FRB to expand its lead over new entrants in the space, propelled by data-driven innovation and an unparalleled team of deeply experienced experts. By expanding hemp seed production both nationally and globally, alongside its young plant program, FRB's production capabilities will multiply in 2020.
"The management team at FRB continues to grow and accumulate decades of expertise in the agricultural and biotech sectors," says Bill Militello, Founder of Militello Capital. "With the acquisition of the Steep Hill genomics R&D team, FRB expands its leadership position and provides unparalleled benefits to the industry."
In conjunction with renowned research facilities such as CRAG and UC Davis, FRB's expanded R&D program is commercializing valuable, unique traits such as disease resistance and yield. In a little more than three years of operations, FRB has built over 160,000 square feet of facilities, acquired a world-class cannabis genomics team and shipped millions of plants to farmers and growers across the country. With this Insider Round, FRB continues to accelerate its growth as the leading agricultural biotech company in hemp and cannabis.
"FRB continues to build on its position as the leader in agricultural biotech for the hemp and cannabis industries," says Chi-Chien Hou, Managing Director at AFI Capital Partners. "The combination of FRB's robust breeding program and their scaled tissue culture propagation results in tangible benefits for its customers by generating rigorous plants with higher yields and more selective expression."
For more information on Front Range Biosciences, please visit http://www.frontrangebio.com
About Front Range Biosciences
Front Range Biosciences is an agricultural biotech company that specializes in tissue culture propagation breeding of high-value crops at industrial scale to improve consistency and efficiency for clone and seed production. FRB developed the first Clean Stock�® program for cannabis and hemp and has an advanced breeding program for identifying and improving commercially relevant traits. FRB has global reach through facilities in Colorado, California, and Wisconsin, and partnerships with the University of California Davis and the Center for Research in Agricultural Genomics in Barcelona, Spain. FRB's Clean Stock program provides a consistent supply of disease and pest free plants to farmers and data-driven breeding solutions for creating new varieties of hemp, coffee, and young plants and seeds. FRB is located in Lafayette, Colorado.
Funding Events
Date | Amount | Type | Investors | Lead investor |
---|---|---|---|---|
20/09/2017 | $3,000,000 | Bridge | Anthill Ventures, Canopy Ventures, Halley Venture Partners, HBS Alumni Angels of Greater New York, New York Angels, Phyto Partners, Salveo Capital, Sand Hill Angels | |
05/10/2018 | $10,000,000 | Series A | Altitude Investment Partners, Cornerstone Opportunity Partners, HBS Alumni Angels of Greater New York, New York Angels, Phyto Partners, Salveo Capital, Sand Hill Angels, Welcan Capital | |
16/09/2019 | $8,500,000 | AFI Capital Partners, Arcadian New Venture Fund, Halley Venture Partners, Harvard Business School Angels, Militello Capital, New York Angels, Phyto Partners, Salveo Capital, Sand Hill Angels, Welcan Capital |